The joumal uses Crossref ited-by service counts times cited of published aricles. Citedby allows Crossref members to find out who is citing their conten. This is the Citing Article List of “Immune checkpoint inhibitor-induced hemophagocytic lymphohistiocytosis in lung cancer: a case series”.
|
No. |
Publication Date |
Citing Article |
|
1 |
2025 |
, Atezolizumab/Pembrolizumab, Reactions Weekly. 2025; 2089: 23. https://doi.org/10.1007/s40278-025-91538-2 |
|
2 |
2026 |
Yewei Cai, Tianxing Ni. The impact of obesity-related systemic inflammation on the efficacy, toxicity, and biomarkers of immune checkpoint inhibitors in lung cancer: from mechanisms to clinical management, Frontiers in Immunology. 2026; 17: 1757711. https://doi.org/10.3389/fimmu.2026.1757711 |
|
3 |
2026 |
Abdulrahman F. Al-Mashdali, Fatihelmgib Mohamed, Marwa Osman, Mujahid O. Abdelraof, Mohammed Abdulgayoom, Shehab F. Mohamed. Immune Checkpoint Inhibitor–Associated Hemophagocytic Lymphohistiocytosis: A Systematic Review, Clinical Medicine Insights: Oncology. 2026; 20: 11795549261489492. https://doi.org/10.1177/11795549261489492 |
|
4 |
2026 |
Connor Frey, Comparative pharmacovigilance signals for PD-1, PD-L1, CTLA-4, and LAG-3 immune checkpoint inhibitor-associated hemophagocytic lymphohistiocytosis in the FAERS database, Journal of Oncology Pharmacy Practice. 2026; 10781552261443222. https://doi.org/10.1177/10781552261443222 |